The Shanghai-based biotech firm is set to highlight its progress in targeted cancer therapies at the IFEMA MADRID Convention Center. On October 25, the company will present findings from the CLINCH study regarding ATG-022, a Claudin 18.2 antibody-drug conjugate currently under evaluation for advanced gastric and gastroesophageal junction cancers.
Antengene to Present Clinical Data for ATG-022 and ATG-037 at ESMO 2026
Antengene Corporation will showcase new clinical findings for its lead oncology candidates during the European Society for Medical Oncology Annual Congress in Madrid this October. The presentations cover Phase 2 results for a Claudin 18.2 antibody-drug conjugate and updated data on a small-molecule inhibitor for resistant melanoma.
Earlier in the congress, on October 24, researchers will discuss updated results from the STAMINA-01 trial. This session focuses on the efficacy and safety of combining the oral CD73 inhibitor ATG-037 with pembrolizumab in patients battling melanoma resistant to checkpoint inhibitors. These clinical milestones underscore the company’s ongoing efforts to advance its pipeline of first-in-class therapeutics for solid tumors and hematological malignancies.
Comments (0)
No comments yet. Be the first!